Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Claire Ellender

Physician Assistant, Surgical Germantown, TN Physician Assistant

NPI 1033223599 CMS profile 10951913

7655 Poplar Ave Ste 240, Germantown, TN 38138

Open in the dashboard

General payments

$3,581

132 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Claire Ellender of Germantown, TN is reported in the CMS Open Payments database as having received $3,581 across 132 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $870 9
2024 General $1,205 64
2023 General $691 19
2022 General $219 14
2021 General $595 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Claire Ellender
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Claire Ellender were reported at $870. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Claire Ellender Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $595 $111 $36–$285 $132
2022 $219 $126 $44–$350 $149
2023 $691 $137 $47–$355 $160
2024 $1,205 $146 $49–$384 $164
2025 $870 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Intuitive Surgical, Inc. $818 7 payments
  2. AbbVie, Inc. $538 20 payments
  3. Novo Nordisk Inc $435 16 payments
  4. AstraZeneca Pharmaceuticals LP $404 16 payments
  5. GlaxoSmithKline, LLC. $245 16 payments
  6. Lilly USA, LLC $176 11 payments
  7. Edwards Lifesciences Corporation $149 2 payments
  8. Janssen Pharmaceuticals, Inc $104 7 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $64 4 payments
  10. Hologic, LLC $64 3 payments
  11. Other $583 30 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,778 125 payments
  2. Travel and Lodging $701 5 payments
  3. Education $101 2 payments
Products named General payments · program years 2021–2025
  1. Da Vinci Surgical System $718 6 payments
  2. UBRELVY $403 14 payments
  3. RYBELSUS $342 11 payments
  4. TRELEGY ELLIPTA $245 16 payments
  5. Ozempic $240 10 payments
  6. FARXIGA $183 5 payments
  7. MOUNJARO $155 9 payments
  8. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $148 1 payment
  9. QULIPTA $136 3 payments
  10. AIRSUPRA $127 6 payments
  11. Other $1,356 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

777

Median for Physician Assistant: 241

Drug cost

$62,049

Median for Physician Assistant: $4,110

Branded share of claims

23.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 26 $25,817
Ozempic Semaglutide Brand 16 $16,220
Jardiance Empagliflozin Brand 15 $10,008
Tresiba Flextouch U-100 Insulin Degludec Brand 11 $2,355
Paxlovid Nirmatrelvir/Ritonavir Brand 27 $1,429
Gabapentin Generic 44 $583
Pantoprazole Sodium Generic 29 $561
Losartan Potassium Generic 37 $403
Atorvastatin Calcium Generic 42 $402
Amlodipine Besylate Generic 45 $378

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 79 billing codes

Paid by Medicare

$54,277

Of which drugs: $3,589

Medicare patients

332

Average age 74

Services billed

2,652

250 women, 82 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Diabetes 27%
Chronic kidney disease 26%
Ischemic heart disease 24%
Osteoporosis 23%
Depression 22%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 20 20 $1,636
Injection, methylprednisolone acetate, 1 mg J1010 Office 11 440 $40
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 13 69 $36
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 26 145 $9

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $127
$127 — —
RYBELSUS
  • Novo Nordisk Inc $126
$126 — —
MOUNJARO
  • Lilly USA, LLC $116
$116 26 —
Ozempic
  • Novo Nordisk Inc $103
$103 16 —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $88
$88 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

132 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record